IMMUNOME INC (IMNM)
US45257U1088 - Common Stock
Immunome Appoints Sandra M. Swain to Board of Directors
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immunome (NASDAQ:IMNM) just reported results for the fourth quarter of 2023.Imm...
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Immunome to Participate in the Leerink Partners Global Biopharma Conference
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined Benzinga's PreMarket Prep on Tuesday and discussed the biotech industry and Viking Therapeutics and Immunome as notable recent movers.
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Investors Snag IMNM Even Lower Than Its Secondary Stock Offering
Immunome down 1%, prices $200M equity (NASDAQ:IMNM)
Biotechnology company Immunome prices underwritten public offering of 10M shares at $20.00 per share, expecting $200M gross proceeds.
Immunome Announces Pricing of Public Offering of Common Stock
Immunome files for automatic mixed securities shelf (NASDAQ:IMNM)
Immunome (IMNM) has filed a prospectus for the offer and sale of automatic mixed securities shelf.
Immunome announces underwritten public offering of common stock (NASDAQ:IMNM)
Immunome (IMNM) plans $200 million public offering of common stock with an option for underwriters to purchase additional shares.
Immunome Announces Proposed Public Offering of Common Stock
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Top Buys by Directors: Siegall's $1000K Bet on IMNM
Top Buys by Top Brass: CEO Siegall's $1000K Bet on IMNM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
Immunome appoints Phil Roberts as chief technical officer (NASDAQ:IMNM)
Immunome announces the appointment of Phil Roberts as Chief Technical Officer.
Immunome Appoints Phil Roberts as Chief Technical Officer
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Immunome Appoints Carol A. Schafer to Board of Directors
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Immunome a new outperform at Wedbush on cancer platforms
Wedbush initiates Immunome at outperform, highlighting its potential to develop effective antibody therapies for cancer. Read more here.
Immunome Enters Oversold Territory (IMNM)
Immunome files to sell 21.7M shares for holders (NASDAQ:IMNM)
Immunome (IMNM) files prospectus for resale of 21.7 million common shares.